ArticleDiabetes2009
Pig embryonic pancreatic tissue as a source for transplantation in diabetes: transient treatment with anti-LFA1, anti-CD48, and FTY720 enables long-term graft maintenance in mice with only mild ongoing immunosuppression.
Article in Diabetes, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Feasibility of large experimental animal models in testing novel therapeutic strategies for diabetes.World journal of diabetes · 2021Review
- Bioinformatics analyses on the immune status of renal transplant patients, a systemic research of renal transplantation.BMC medical genomics · 2020Article
- Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.Immunological reviews · 2017Review
- Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation.Frontiers in pharmacology · 2017Article
- Roles of CD48 in regulating immunity and tolerance.Clinical immunology (Orlando, Fla.) · 2016Review
- Preconditioning allows engraftment of mouse and human embryonic lung cells, enabling lung repair in mice.Nature medicine · 2015Article
- From Beta cell replacement to beta cell regeneration: implications for antidiabetic therapy.Journal of diabetes science and technology · 2014Review
- Optimal pig donor selection in islet xenotransplantation: current status and future perspectives.Journal of Zhejiang University. Science. B · 2014Review
- Pig-islet xenotransplantation: recent progress and current perspectives.Frontiers in surgery · 2014Review
- Article
- Fetal pancreas as a source for islet transplantation: sweet promise and current challenges.Diabetes · 2013Article
- Xenotransplantation of embryonic pig pancreas for treatment of diabetes mellitus in non-human primates.Journal of biomedical science and engineering · 2013Article
- Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy.PloS one · 2013Article
- Xenografted islet cell clusters from INSLEA29Y transgenic pigs rescue diabetes and prevent immune rejection in humanized mice.Diabetes · 2012Article
- Xenotransplantation of embryonic pig kidney or pancreas to replace the function of mature organs.Journal of transplantation · 2011Article
- Engraftment of insulin-producing cells from porcine islets in non-immune-suppressed rats or nonhuman primates transplanted previously with embryonic pig pancreas.Journal of transplantation · 2011Article
- Engraftment of cells from porcine islets of Langerhans and normalization of glucose tolerance following transplantation of pig pancreatic primordia in nonimmune-suppressed diabetic rats.The American journal of pathology · 2010Article
- Article
- Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Organogenetic tolerance.OrganogenesisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
objectiveDefining an optimal costimulatory blockade-based immune suppression protocol enabling engraftment and functional development of E42 pig embryonic pancreatic tissue in mice. RESEARCH DESIGN AND
methodsConsidering that anti-CD40L was found to be thrombotic in humans, we sought to test alternative costimulatory blockade agents already in clinical use, including CTLA4-Ig, anti-LFA1, and anti-CD48. These agents were tested in conjunction with T-cell debulking by anti-CD4 and anti-CD8 antibodies or with conventional immunosuppressive drugs. Engraftment and functional development of E42 pig pancreatic tissue was monitored by immunohistology and by measuring pig insulin blood levels.
resultsFetal pig pancreatic tissue harvested at E42, or even as early as at E28, was fiercely rejected in C57BL/6 mice and in Lewis rats. A novel immune suppression comprising anti-LFA1, anti-CD48, and FTY720 afforded optimal growth and functional development. Cessation of treatment with anti-LFA1 and anti-CD48 at 3 months posttransplant did not lead to graft rejection, and graft maintenance could be achieved for >8 months with twice-weekly low-dose FTY720 treatment. These grafts exhibited normal morphology and were functional, as revealed by the high pig insulin blood levels in the transplanted mice and by the ability of the recipients to resist alloxan induced diabetes.
conclusionsThis novel protocol, comprising agents that simulate those approved for clinical use, offer an attractive approach for embryonic xenogeneic transplantation. Further studies in nonhuman primates are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.